New Scientific Data at the ESMO Virtual Congress 2020 Reflect Merck’s Commitment to Advancing Cancer Research and Care

Pivotal Studies for KEYTRUDA® (pembrolizumab) in Esophageal Cancer (KEYNOTE-590) and LYNPARZA® (olaparib) in Prostate Cancer (PROfound) Selected for ESMO Presidential Symposium Sessions

https://www.businesswire.com/news/home/20200902005293/en/New-Scientific-Data-ESMO-Virtual-Congress-2020

Leave a comment



Leave a Reply

Your email address will not be published. Required fields are marked *